KR20020090444A - The food to improve the sexual function of man - Google Patents
The food to improve the sexual function of man Download PDFInfo
- Publication number
- KR20020090444A KR20020090444A KR1020010028987A KR20010028987A KR20020090444A KR 20020090444 A KR20020090444 A KR 20020090444A KR 1020010028987 A KR1020010028987 A KR 1020010028987A KR 20010028987 A KR20010028987 A KR 20010028987A KR 20020090444 A KR20020090444 A KR 20020090444A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- sexual function
- food
- sexual
- fructus
- Prior art date
Links
- 230000036299 sexual function Effects 0.000 title claims abstract description 46
- 235000013305 food Nutrition 0.000 title description 9
- 235000013376 functional food Nutrition 0.000 claims abstract description 28
- 229940109850 royal jelly Drugs 0.000 claims abstract description 13
- 241000251511 Holothuroidea Species 0.000 claims abstract description 10
- 235000002789 Panax ginseng Nutrition 0.000 claims description 12
- 241000209020 Cornus Species 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 244000241838 Lycium barbarum Species 0.000 claims description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 235000013527 bean curd Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 241000228212 Aspergillus Species 0.000 claims description 5
- 241001061264 Astragalus Species 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- 241000235070 Saccharomyces Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229910052571 earthenware Inorganic materials 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 235000008434 ginseng Nutrition 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 210000000582 semen Anatomy 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 241000282461 Canis lupus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 description 23
- 208000010228 Erectile Dysfunction Diseases 0.000 description 22
- 230000001568 sexual effect Effects 0.000 description 22
- 238000003780 insertion Methods 0.000 description 21
- 230000037431 insertion Effects 0.000 description 20
- 241000411851 herbal medicine Species 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 240000006079 Schisandra chinensis Species 0.000 description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000003946 Prolactin Human genes 0.000 description 7
- 108010057464 Prolactin Proteins 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229940097325 prolactin Drugs 0.000 description 7
- 239000004576 sand Substances 0.000 description 7
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 235000015468 Lycium chinense Nutrition 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 235000012041 food component Nutrition 0.000 description 5
- 239000005417 food ingredient Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000007758 mating behavior Effects 0.000 description 5
- 229940034208 thyroxine Drugs 0.000 description 5
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 5
- 229940094720 viagra Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035946 sexual desire Effects 0.000 description 4
- 229960003310 sildenafil Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- -1 ginseng Natural products 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011471 prostatectomy Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 240000006670 Chlorogalum pomeridianum Species 0.000 description 1
- 235000007836 Chlorogalum pomeridianum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 208000016207 Male Genital disease Diseases 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000014289 Solanum fendleri Nutrition 0.000 description 1
- 235000009865 Solanum jamesii Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 240000000143 Turnera diffusa Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000004952 turnera diffusa Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 남성의 성기능 개선용 기능성 식품에 관한 것이다.The present invention relates to a functional food for improving sexual function of men.
환경오염, 사회적 스트레스, 성인병 등의 증가로 인하여 남성의 성기능(性機能)이 저하되어 발기부전(***不全), 조루(早漏) 등의 증상이 여러 선진국에서 증가하고 있다. 현대 사회에서 남성의 건강한 性的 능력은 원만한 부부생활을 하기 위한 필수조건이다.Due to increased environmental pollution, social stress, and adult diseases, male sexual function is reduced, and symptoms of erectile dysfunction and premature ejaculation are increasing in various developed countries. Men's healthy sexual abilities in modern society are a prerequisite for a good marital life.
발기부전은 만족스런 성행위에 필요한 발기가 지속적으로 이루어지지 않는 증상으로, 미국의 경우 3천만명의 남성이 발기부전 증상을 보이고 있는데 [JAMA, 270, 83 (1993)] 이 증상은 나이에 따라 40대 남성의 39 %, 70대 남성의 67 %의 빈도로 나타나고 있다 [J. Urol., 151, 54 (1994)].Erectile dysfunction is a condition in which the erection necessary for satisfactory sexual activity is not continuously performed. In the United States, 30 million men have erectile dysfunction [JAMA, 270, 83 (1993)]. 39% of men and 67% of men in their 70s are reported [J. Urol., 151, 54 (1994)].
나이가 듦에 따라 발기부전(***不全, erectile dysfunction)이 증가하지만, 나이가 음위(impotence)의 원인은 아니다. 사정(***, ejaculation)의 양, 힘 및 욕구는 나이와 함께 감소하지만 발기력은 유지된다. 남성은 80대까지 성적 활력을유지할 수 있다.With age, erectile dysfunction increases, but age is not the cause of impotence. The amount, strength and desire of ejaculation decreases with age but erection is maintained. Men can maintain their sexual vitality by age 80.
심리적 요인은 남성의 성적 반응에 확실히 관여하지만, 남성의 성행위에 반드시 필요하지는 않다. 부교감(parasympathetic) 신경계가 발기와 윤활(lubrication)에 관여하고, 교감신경계는 배출(emission)과 사정을 조절한다.Psychological factors are certainly involved in male sexual responses, but are not necessary for male sexual activity. The parasympathetic nervous system is involved in erection and lubrication, and the sympathetic nervous system regulates emission and ejaculation.
발기부전은 육체적(organic) 또는 정신적 요인으로 발생하지만, 육체적(생리적) 요인이 훨씬 많이 작용한다. 실제로 50대 이후의 남성에게 나타나는 발기부전의 90% 이상이 생리적 요인에 기인한다 [Postgraduate Medicine, 93, 65 (1993)]. 과거에는 야간 또는 조조(早朝) 발기 현상을 보이는 남성의 음위는 심리적 요인에 의하여 발생한다고 생각되었으나 현재는 부정되고 있다 [J. Urol., 149, 1246 (1993)].Erectile dysfunction occurs due to physical or mental factors, but physical (physiological) factors are much more active. In fact, more than 90% of erectile dysfunction in men after their 50s is due to physiological factors [Postgraduate Medicine, 93, 65 (1993)]. In the past, it was thought that the tone of males with night or early erections was caused by psychological factors. Urol., 149, 1246 (1993)].
음위의 가장 일반적 원인은 순환기 질환이다. 음경 동맥의 경화는 발기부전을 보이는 50대 이후의 남성 중 약 절반을 차지할 정도로 가장 중요한 원인이다. 동맥경화는 동맥의 혈관 벽에 콜레스테롤, 지방질 및 세포 조각이 쌓여서 굳어지는 현상이다. 동맥경화에 의한 발기부전은 심장병 또는 뇌졸중의 전조(前兆)이다. 동맥경화는 심장이나 남성 성기의 동맥을 포함한 전신에서 발생한다. 발기부전이 순환기 이상에 의한 것이면 심혈관 위험 요인인 콜레스테롤, 트리글리세라이드(triglyceride), 혈압, 비만, 운동부족 및 흡연을 줄여야 한다.The most common cause of the lupus is circulatory disease. Penile arteriosclerosis is the most important cause, accounting for about half of men in their 50s and older who develop erectile dysfunction. Atherosclerosis is a condition in which cholesterol, fat, and cell fragments build up on the walls of blood vessels in an artery. Erectile dysfunction due to atherosclerosis is a precursor to heart disease or stroke. Atherosclerosis occurs throughout the body, including the arteries of the heart or male genital organs. If erectile dysfunction is due to circulatory problems, cardiovascular risk factors such as cholesterol, triglycerides, blood pressure, obesity, lack of exercise and smoking should be reduced.
현재 알려져 있는 음위의 원인을 요약하면 다음과 같다.The causes of the known harmonics are as follows.
육체적(85%)Physical (85%)
순환기 장애: 동맥경화, 골반 수술, 골반 외상, 정맥 우회Circulatory Disorders: Arteriosclerosis, Pelvic Surgery, Pelvic Trauma, Intravenous Bypass
의약품: 항히스타민제, 항고혈압제, 항콜린제, 항우울제, 항정신병제, 진정제, 기타Drugs: antihistamines, antihypertensives, anticholinergics, antidepressants, antipsychotics, sedatives, other
술과 담배Alcohol and Tobacco
내분비 이상: 당뇨병, 갑상선 기능 저하, 남성 호르몬(hormone) 감소, 프로락틴 (prolactin) 증가, 혈청 에스트로젠(estrogen) 증가Endocrine disorders: Diabetes, reduced thyroid function, decreased testosterone, increased prolactin, increased serum estrogen
남성 성기관의 질환 또는 외상: 남성 성기 질환, 전립선 이상Male sexual organ disease or trauma: male genital disease, prostate abnormalities
신경계 질환: 골반 외상, 골반 수술, 다중 경화Nervous system diseases: pelvic trauma, pelvic surgery, multiple sclerosis
심리적(10%)Psychological (10%)
정신질환: 스트레스, 성취 불안, 우울Mental Illness: Stress, Achievement Anxiety, Depression
미정(5%)TBD (5%)
여러 가지 내분비계와 호르몬의 이상이 발기부전을 유발한다. 가장 일반적인 이상이 당뇨병인데 당뇨병은 동맥경화와 음위를 일으키는 신경손상의 위험인자이다. 음위와 관련된 비교적 흔한 내분비계 이상에는 갑상선 기능저하, 프로락틴 증가 및 테스토스테론(testosterone) 감소 (생식기능 저하)가 있다.Various endocrine and hormone abnormalities cause erectile dysfunction. The most common abnormality is diabetes, which is a risk factor for neurological damage that causes arteriosclerosis and tonic. Relatively common endocrine dysfunctions associated with the negative position include hypothyroidism, increased prolactin and decreased testosterone (reproductive function).
브로멜라인(bromelain)은 파인애플의 단백질 분해 효소인데 피브린(fibrin)의 축적을 예방한다. 피브린의 축적은 페이로니씨병(Peyronie's disease)에서 성기의 섬유성 결합조직의 비대요인으로 알려져 있다.Bromelain is a proteolytic enzyme of pineapple that prevents the accumulation of fibrin. Fibrin accumulation is known as a hypertrophy of the genital fibrous connective tissue in Peyronie's disease.
아연은 성기능에 가장 중요한 영양소이다. 아연은 정액에 농축되어 있다. 빈번한 사정은 체내의 아연량을 크게 감소시킨다. 아연이 부족하면 성욕이 감소한다.Zinc is the most important nutrient for sexual function. Zinc is concentrated in semen. Frequent ejaculation greatly reduces the amount of zinc in the body. Lack of zinc reduces libido.
성기능에 중요한 다른 영양소로 필수 지방산, 비타민 A, 비타민 B6및 비타민 E가 있다.Other nutrients that are important for sexual function are essential fatty acids, vitamin A, vitamin B 6 and vitamin E.
나이아신(niacin)은 콜레스테롤 저하에 특히 효과적이다. 음위와 고콜레스테롤증에는 나이아신의 보다 안전한 형태인 이노지톨 헥사나이아시네이트 (inositol hexaniacinate)의 섭취가 권장되고 있다. 발기부전의 경우 이노지톨 헥사나이아시네이트는 혈액순환을 개선하기도 한다. 항산화 영양소인 비타민 C와 E, β-카로틴(carotene) 및 셀레니움(selenium)은 동맥경화와 심장병을 예방한다 [Arch. Intern. Med., 148, 136 (1988)].Niacin is particularly effective in lowering cholesterol. Ingestion and hypercholesterolemia is recommended to take inositol hexaniacinate, a safer form of niacin. In the case of erectile dysfunction, inositol hexanaisinate may also improve blood circulation. Antioxidant nutrients, vitamins C and E, β-carotene and selenium, prevent arteriosclerosis and heart disease [Arch. Intern. Med., 148, 136 (1988)].
영양 및 운동과 함께 생약재가 발기부전에 대한 자연요법으로 많이 사용되고 있다. 남성 내분비 기관의 활력을 높이거나 발기조직에 혈액공급을 증가시키며 신경 신호의 전달이나 자극을 증가시키는 약초를 활용하면 성적 욕구나 기능을 개선시킬 수 있다.Along with nutrition and exercise, herbal medicines are widely used as natural therapies for erectile dysfunction. Herbs that increase the vitality of male endocrine organs, increase blood supply to erectile tissues, and increase the transmission or stimulation of nerve signals can improve sexual desire or function.
한의학(韓醫學)에서 음위증은 성욕은 있으나 음경(陰莖)이 제대로 발기되지 않는 증상으로 신기(腎氣)나 명문(命門)의 화(火)가 부족한 때, 심한 정신적 타격으로 심비(心脾)가 상하거나 간신증(肝腎陰)이 허(虛)하여 허화(虛火)가 떠오를 때, 외상, 습열(濕熱)이 아래에 몰려서 종근(宗筋)이 이완되었을 때 생긴다고 설명하고 있다 [과학백과사전종합출판사, 1989, 東醫學辭典, 여강출판사, 서울 (1989)]. 신기가 부족하거나 명문의 화가 부족하여 생긴 때는 얼굴에 핏기가 없으며 어지러움증과 이명(耳鳴)이 생기며 허리가 시큰시큰하고 다리가 시리며 추위를탄다. 습열자(濕熱者)의 음위는 간비(肝脾)에 속하고, 허자(虛者)의 음위는 페신(肺腎)에 속한다 [李時珍, 圖解 本草綱目, 고문사, 서울 (1987)].In oriental medicine, vulgaris is a symptom of sexual desire, but the penis is not properly erected. It is explained that it is caused when trauma, moist heat gathers underneath, and the Chong muscle is relaxed when the wound is damaged due to spontaneous injury or hepatic dysfunction. Encyclopaedia Publishers, 1989, 東 醫學 辭典, Yeogang Publishers, Seoul (1989)]. When lack of wear or lack of prestige, there is no blood on the face, dizziness and tinnitus occurs, and the waist is dark and the legs are cold and cold. The humid genius belongs to Ganbi and the fictional genus belongs to Fezin [李 時珍, 圖解 本草綱目, Torture History, Seoul (1987)].
대독(大毒)으로 병을 치료하면 6할(割)이 치료되고, 보통의 독으로 치료하면 7할이 치료되고, 소독(小毒)으로 치료하면 8할이 치료되며 무독(無毒)으로 치료하면 9할이 치료된다. 곡육과채(穀肉果菜)를 잘 조절하여 먹으면 병을 근치(根治)할 수 있다. 보초학(本草學)에서 생약재를 상품(上品), 중품(中品), 하품(下品)의 삼품(三品)으로 분류하고 있는데 이중 상품의 약은 많은 양을 오래 먹어도 부작용이 없고 사람을 건강하고 오래 살게 한다고 기록하고 있다 [東醫寶鑑國譯委員會 編譯, 國譯增補東醫寶鑑, 南山堂, 서울 (1988)]. 이러한 한의학(韓醫學) 이론은 음식을 통하여 병의 근치가 가능하고, 여러 가지 무독한 생약재를 활용하여 현대 서양의학으로 치료가 어려운 성인병을 예방하고 억제할 수 있는 기능성 식품을 개발할 수 있는 가능성을 제시하고 있다.If you treat the disease with Daepok, 60% is cured. If you treat with ordinary poison, 70% is cured. If you treat with disinfection, 80% is cured. 90% will be healed. Grain meat and vegetable (穀 肉 果菜) well controlled by eating the disease can be cured (根治). Herbal medicine classifies herbal medicines as commodities, intermediates, and yawns. Three of these drugs have no side effects and can be healthy for people. It has been recorded to live longer [東 醫 寶 鑑 國 譯 委員會 編譯, 國 譯 增補 東 醫 寶 鑑, 南山 堂, Seoul (1988)]. The theory of Korean medicine suggests the possibility of developing functional foods that can cure diseases through food and utilize various non-toxic herbal medicines to prevent and suppress adult diseases that are difficult to treat with modern western medicine. Doing.
성적 자극을 받으면 남성 성기의 해면체에서 일산화질소(nitric oxide, NO)가 생성된다. NO는 구아닐레이트 싸이클레이즈 (guanylate cyclase)를 활성화시키고 싸이클릭 구아노신 모노포스패이트 (cyclic guanosine monophosphate, cGMP)의 농도를 높여서 해면체의 평활근을 이완시켜 혈액을 유입시킨다. 미국의 파이자(Pfizer)사에서 개발되었으며 실데나필 사이트래이트 (sildenafil citrate) (비아그라, Viagra)로 알려진 1-[[3-(6,7-다이하이드로-1-메틸-7-옥소-3-프로필-1H-피라졸로[4,3-d]피리미딘-5-yl)-4-에톡시페닐]설포닐]-4-메틸피페라진 사이트래이트 (1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate)는 해면체에서 cGMP를 분해시키는 포스포다이에스터래이즈(phosphodiesterase) 타입(type) 5 (PDE5)를 억제하여 NO의 효과를 증가시킨다. 1998년 FDA의 승인과 함께 시판된 실데나필(sildenafil, Viagra)를 복용하고 약 1시간이 지나면 60-80%의 환자가 성적 자극과 함께 발기를 일으킨다. 실데나필은 정신적 또는 관상동맥 질병, 말초혈관 질환, 당뇨병, 우울증, 관상동맥 우회 이식, 급격한 전립선 절제수술, 요도 경유 전립선 절제, 척추 손상 등의 모든 물리적 요인에 의한 발기부전에 효과적이다. 또한 실데나필은 항우울제, 항정신병약, 항고혈압제 및 이뇨제의 복용에 의한 발기부전에도 효과적이다. 부작용으로 두통, 근육통, 홍조, 소화불량, 비충혈(鼻充血), 색맹, 광 민감성, 시력 저하 등을 수반하며 심장병 약과 함께 복용될 경우 사망의 원인이 되기도 하며 가격도 고가인 편이다.Sexual stimulation produces nitric oxide (NO) in the corpus cavernosum of the male genitals. NO activates guanylate cyclase and raises the concentration of cyclic guanosine monophosphate (cGMP) to relax the cavernous smooth muscle and introduce blood. Developed by Pfizer, USA and known as sildenafil citrate (Viagra), 1-[[3- (6,7-dihydro-1-methyl-7-oxo-3- Propyl-1H-pyrazolo [4,3-d] pyrimidine-5-yl) -4-ethoxyphenyl] sulfonyl] -4-methylpiperazine citrate (1-[[3- (6,7) -dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl) -4-ethoxyphenyl] sulfonyl] -4-methylpiperazine citrate) breaks down cGMP in the corpus cavernosum Inhibition of phosphodiesterase type 5 (PDE5) increases the effect of NO. Approximately one hour after taking sildenafil (viagra), marketed with FDA approval in 1998, about 60-80% of patients develop an erection with sexual stimulation. Sildenafil is effective for erectile dysfunction due to all physical factors such as mental or coronary artery disease, peripheral vascular disease, diabetes, depression, coronary artery bypass graft, abrupt prostatectomy, prostatectomy via urethra and spinal cord injury. Sildenafil is also effective in erectile dysfunction by taking antidepressants, antipsychotics, antihypertensives and diuretics. Side effects include headache, muscle pain, flushing, indigestion, nasal congestion, color blindness, light sensitivity, and decreased vision, and when taken with heart disease, can cause death and are expensive.
우리 나라의 태평양 제약에서 시판하고 있으며 육종용, 계피, 세신 등의 생약재를 원료로 하여 제조된 SS크림 등 다른 발기부전 개선제 역시 발기부전의 원인이 되는 혈액순환, 내분비 기능 등에 관련된 신체의 장애를 개선시키지 않고 일시적인 발기를 유도에 초점을 두고 개발되어 사용함에 따라 내성이 생기거나 여러 가지 부작용이 나타날 수 있다.It is marketed by Pacific Pharmaceuticals in our country, and other erectile dysfunction agents, such as SS cream, made from herbal medicines such as sarcoma, cinnamon and sessin, do not improve the body's disorders related to blood circulation and endocrine function, which cause erectile dysfunction. The development and use of temporary erections with the focus on induction can lead to tolerance or various side effects.
프랑스에서는 천연 생약재 및 식품소재를 원료로 하여 발기부전을 억제하는 강정용 건강식품인 티그라(Tigra)를 개발하여 시판중이며 개당 가격이 약 2,200원으로 개당 가격이 약 8,700∼12,500원인 비아그라에 비해 싸다. 티그라의 원료는 인삼, 멕시코 강장제인 다미아나(damiana), 노화방지제 DHEA의 원료인 야생감자얌(yam), 정향유, 항우울 효과가 있는 박하 등 천연물이며 비아그라에서 나타나는 부작용이 없다고 한다.In France, Tigra, a health food for jeongjeong, which suppresses erectile dysfunction, is commercially available using natural herbal and food ingredients, and is priced at about 2,200 won each and cheaper than Viagra, which is about 8,700 to 12,500 won each. Tigra's ingredients are natural products such as ginseng, damiana, a Mexican tonic, wild potato yam, clove oil, and peppermint with an antidepressant effect.
미국의 경우 막대한 연구비를 암, 관절염, 고혈압, 당뇨병, 발기부전 등과 같은 만성 성인병의 연구에 투자하고 있고 많은 의료비가 지출되고 있지만 이들 질환의 치료와 예방이 잘 되지 못하고 있다. 따라서 미국을 비롯한 여러 선진국들은 지금까지 개발된 의약품들에 비하여 비교적 부작용이 적은 생약재 및 식품소재(nutraceuticals)를 이용한 성인병 치료에 대한 관심이 높아지고 있다.In the United States, a huge amount of research has been invested in the study of chronic adult diseases such as cancer, arthritis, high blood pressure, diabetes, and erectile dysfunction, and many medical expenses are being spent, but the treatment and prevention of these diseases is not well done. Therefore, many developed countries, including the United States, are increasing interest in treating adult diseases using herbal medicines and nutraceuticals, which have relatively fewer side effects than drugs developed so far.
미국의 파이자사에서 개발된 비아그라는 두통, 근육통, 위장장애 등의 부작용을 초래하며 심장병 약과 함께 복용될 경우 사망의 원인이 되기도 하며 다른 발기부전 개선제 역시 발기부전의 원인이 되는 혈액순환, 내분비 기능 등에 관련된 신체의 장애를 개선시키지 않고 일시적인 발기를 유도에 초점을 두고 개발되어 사용함에 따라 내성이 생기거나 여러 가지 부작용이 나타날 수 있다. 따라서 혈액의 순환을 촉진하고 호르몬의 분비를 조절하는 생약재 및 식품소재의 강정활성 물질을 추출하고 이를 배합하여 남성 성기능 저하의 원인이 되는 신체의 장애를 근본적으로 개선시키는 성기능 개선용 기능성 식품이 요구되고 있다.Viagra, developed by Paizar in the United States, causes side effects such as headache, muscle pain, and gastrointestinal disorders, and when taken with heart disease medications, can cause death. Other erectile dysfunction agents also include blood circulation and endocrine functions, which cause erectile dysfunction. As a result of the development and use of temporary erections without improving the disability involved, resistance or other side effects may occur. Therefore, there is a need for functional food for improving sexual function, which extracts and combines the strong active substances of herbal medicines and food materials that promote blood circulation and regulate hormone secretion, and fundamentally ameliorate the disorders of the body that cause male sexual dysfunction. have.
본 발명자들은 혈액의 순환을 촉진하고 호르몬의 분비를 조절하는 생약재 및 식품소재의 남성 성기능 개선 활성을 동물실험을 통하여 조사하고 이들을 배합하여 남성 성기능 저하의 원인이 되는 신체의 장애를 근본적으로 개선시키는 남성의 성기능 개선용 기능성 식품 개발하고 그 효과를 임상실험을 통하여 입증하고 본 발명을 완성하였다.The present inventors investigated the male sexual function improving activity of herbal medicines and food materials that promote blood circulation and regulate hormone secretion through animal experiments, and combining them to improve the physical disorders of the body that causes male sexual decline. Development of functional foods for improving sexual function and proved its effectiveness through clinical trials and completed the present invention.
기술적 수단Technical means
본 발명은 위스타(Wistar)계 숫쥐 실험에서 우수한 성기능 개선 활성을 보인 12종의 식품소재 및 식품원료로 사용가능한 생약재 즉, 복분자, 구기자, 산수유, 오미자, 백복령, 사상자, 토사자, 우슬, 두충, 홍삼, 해삼 및 로얄 젤리와 황기, 박하, 감초를 활용한 남성 성기능 개선용 기능성 식품 및 그의 제조방법을 제시한다.In the present invention, 12 kinds of food ingredients and raw materials that can be used as food ingredients, that is, the medicinal herbs, Bokbunja, Gojija, Cornus, Schisandra chinensis, Baekbokryeong, Casualties, Sasa, Wooslung, Tofu, A functional food for improving male sexual function using red ginseng, sea cucumber and royal jelly, and Astragalus, peppermint, and licorice, and a manufacturing method thereof.
본 발명을 이하에 보다 상세히 설명한다.The present invention is explained in more detail below.
본 발명에서 사용되는 모든 생약재는 통상의 방법에 따라 법제(法製)한다.All herbal medicines used in the present invention are prepared according to a conventional method.
본 발명에서 남성 성기능 개선용 기능성 식품에 배합되는 원료의 양은 중량기준으로, 복분자 8∼14%, 구기자 8∼14%, 산수유 6∼12%, 오미자 6∼12%, 백복령 6∼12%, 황기 5∼11%, 사상자 4∼10%, 토사자 4∼10%, 우슬 2∼8%, 박하 2∼8%, 감초 2∼8%, 두충 1∼7%, 홍삼 1∼7%, 해삼 1∼7% 및 로얄 젤리 1∼3%가 바람직하다.In the present invention, the amount of the raw material blended into the functional food for improving male sexual function is 8-14% of Bokbunja, 8-14% of Goji berries, 6-12% of Cornus oil, 6-12% of Schisandra chinensis, 6-12% of Baekbyeongyeong, Astragalus 5-11%, casualties 4-10%, earth and sand 4-10%, dew 2-8%, mint 2-8%, licorice 2-8%, tofu 1-7%, red ginseng 1-7%, sea cucumber 1-10 7% and royal jelly 1-3% are preferred.
남성 성기능 개선 활성을 증가시키기 위하여 위 배합 원료의 혼합물에 아스퍼질러스 오리재 (Aspergillus oryzae)와 사카로마이시즈 세리비지애 (Saccharomyces cerevisiae) 균주를 접종시켜 고체발효한다.Aspergillus duckwood in a mixture of the above ingredients to increase male sexual functionAspergillus oryzae) And Saccharomyces serie businessSaccharomyces cerevisiae) Inoculate the strain to solid fermentation.
본 발명에 따른 기능성 식품 조성물에 함유되는 성분은 모두 식품소재 및 식품원료로 사용가능한 생약재로 인체에 무해하다고 알려져 있다.All ingredients contained in the functional food composition according to the present invention are known to be harmless to the human body as a herbal medicine that can be used as a food material and food ingredients.
본 발명에 따른 조성물은 통상의 방법에 따라 분말화하거나 추출하여 분말, 과립, 정(錠), 캡슐, 음료, 고(膏), 환(丸) 등의 형태로 제형화할 수 있다.The composition according to the present invention may be formulated in the form of powder, granules, tablets, capsules, beverages, granules, pills and the like by powdering or extracting according to a conventional method.
이하, 실시예에 의해 본 발명을 보다 상세히 설명하지만 본 발명이 이들 실시예에 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
실시예Example
실시예 1: 복분자 11%, 구기자 11%, 산수유 9%, 오미자 9%, 백복령 9%, 황기 8%, 사상자 7%, 토사자 7%, 우슬 5%, 박하 5%, 감초 5%, 두충 4%, 홍삼 4%, 해삼 4% 및 로얄 젤리 2%를 통상의 방법에 따라 이물질을 제거한 후 세절하여Example 1 Bokbunja 11%, Gojijaja 11%, Cornus 9%, Schisandra chinensis 9%, Baekbokryeong 9%, Astragalus 8%, Casualties 7%, Tosa 7%, Hail 5%, Peppermint 5%, Licorice 5%, Tofu 4 %, Red ginseng 4%, sea cucumber 4% and royal jelly 2%
40∼80℃에서 열풍건조시키고 입도 60메쉬로 분말화하였다.Hot air dried at 40-80 ° C. and powdered to a particle size of 60 mesh.
실시예 2: 복분자 11%, 구기자 11%, 산수유 9%, 오미자 9%, 백복령 9%, 황기 8%, 사상자 7%, 토사자 7%, 우슬 5%, 박하 5%, 감초 5%, 두충 4%, 홍삼 4%, 해삼 4% 및 로얄 젤리 2%를 이물질을 제거한 후 세절하여 121℃에서 15분간 가압가열 살균하였다. 멸균수 25%를 첨가하고 차펙 용액 아가 (Czapek solution agar) 배지 [In Parks, L. C. (ed), Handbook of Microbiological Media, CRC Press, Boca Raton, p. 280 (1993)]에서 배양된 아스퍼질러스 오리재 (Aspergillus oryzae) SH균주의 포자 현탁액 (1.0 x 109spores/ml)과 사카로마이시즈 세리비지애 (Saccharomyces cerevisiae) SH 균주 세포 현탁액 (1.0 x 109cells/ml)을 각각 2% 접종하고 30℃, 상대습도 70±5% 조건에서 3일간 배양하였다. 발효물을 40∼80℃에서 열풍건조시키고 입도 60메쉬로 분말화하였다.Example 2 Bokbunja 11%, Gojijaja 11%, Cornus 9%, Schisandra chinensis 9%, Baekbokryeong 9%, Astragalus 8%, Casualties 7%, Tosa 7%, Hail 5%, Peppermint 5%, Licorice 5%, Tofu 4 %, Red ginseng 4%, sea cucumber 4% and royal jelly 2% was removed after the removal of foreign matter and sterilized under pressure at 121 ℃ for 15 minutes. 25% sterile water was added and the Czapek solution agar medium [In Parks, L. C. (ed), Handbook of Microbiological Media, CRC Press, Boca Raton, p. 280 (1993)] aspergillus duckwood (Aspergillus oryzae) Spore suspension of SH strain (1.0 x 109spores / ml) and Saccharomyces cerevisiae (Saccharomyces cerevisiae) SH strain cell suspension (1.0 x 109cells / ml) were inoculated at 2% and incubated for 3 days at 30 ° C and 70 ± 5% relative humidity. The fermented product was hot air dried at 40-80 ° C. and powdered to a particle size of 60 mesh.
실시예 3: 실시예 2에서 제조한 분말에 정제수 40중량%를 가하여 고속회전 혼합기로 과립을 형성하여 50∼60℃의 열풍건조기에서 건조시킨 후 15메쉬의 오실레이터를 통과시켜 균일한 입도의 과립을 얻었다.Example 3: 40 wt% of purified water was added to the powder prepared in Example 2 to form granules using a high speed rotary mixer, dried in a hot air dryer at 50 to 60 ° C, and then passed through an oscillator of 15 mesh to obtain granules having a uniform particle size. Got it.
실시예 4: 실시예 3에서 제조한 과립을 통상의 방법에 따라 타정(打錠)하여 정제(각 200㎎)을 수득하였다.Example 4: The granules prepared in Example 3 were compressed into tablets according to a conventional method to obtain tablets (200 mg each).
실시예 5: 상기 실시예 2에서 수득된 분말을 통상의 방법에 따라 경질 젤라틴 캡슐(각 400㎎)에 충전하였다.Example 5: The powder obtained in Example 2 was filled into hard gelatin capsules (400 mg each) according to a conventional method.
실시예 6: 상기 실시예 2에서 수득된 발효물에 20배의 물을 가하고 70℃에서 1시간 추출하였다. [비타민-미네랄 혼합물의 조성은 실시예 2와 동일] 원심분리 후 고형분에 다시 20배의 물을 가하여 동일한 조건에서 추출한 후 원심분리하였다. 고체 잔류물을 버리고 두 추출액을 합쳐 50℃에서 감압(30 - 50 mmHg)농축하여 추출전 조성물 중량의 2배가 되게 하고 3 미크론 필터로 여과하여 75 - 80℃에서 30분간 멸균시킨 후 200메쉬의 여과장치를 통과시켜 여액을 미리 살균된 용기에 충전밀봉하여 음료로 한다.Example 6: 20 times of water was added to the fermented product obtained in Example 2, and extracted at 70 ° C for 1 hour. [The composition of the vitamin-mineral mixture is the same as in Example 2] After centrifugation, 20 times of water was added to the solid, extracted under the same conditions, and centrifuged. Discard the solid residue, combine the two extracts and concentrate under reduced pressure (30-50 mmHg) at 50 ° C to double the weight of the composition before extraction, filter with a 3 micron filter and sterilize at 75-80 ° C for 30 minutes, then filter 200 mesh Through the device, the filtrate is filled and sealed in a pre-sterilized container to be a beverage.
실시예 7: 상기 실시예 6에서 수득된 추출물을 감압가열농축 및 가열농축시켜 고(膏)를 제조한다.Example 7: The extract obtained in Example 6 was heated under reduced pressure and concentrated to prepare a solid.
실시예 8: 상기 실시예 2에서 수득된 분말에 20%의 잡화꿀을 넣어 통상의 방법에 따라 중량 140mg의 환을 제조하였다.Example 8: 20% of miscellaneous honey was added to the powder obtained in Example 2, to prepare a ring having a weight of 140 mg according to a conventional method.
실험예Experimental Example
실험예 1: 남성 성기능 개선 효과 실험 (동물실험)Experimental Example 1: Male sexual function improvement effect experiment (animal experiment)
(1) 동물(1) animals
시료의 강정활성을 조사하기 위하여 위스타(Wistar)계 웅성쥐 (male rat, 5-6 주령, 체중 180-240 g)와 수용성 자성쥐 (receptive female rat)를 사용하였다. 웅성쥐는 2주간 조용한 방 안의 케이지(cage)에 한 마리 씩 넣어졌으며, 주야의 조명은 실험의 편리상 인위적으로 바꾸었다. 시판 펠렛(pellet) 사료와 물을 임의로 먹게 하였으며 표준 실험실 조건 (온도 20-25℃, 상대습도 60-70%)에서 사육되었다.Wistar male rats (male rat, 5-6 weeks old, body weight 180-240 g) and receptive female rats were used to investigate the antistatic activity of the samples. Males were placed in cages in a quiet room for two weeks, and day and night lighting was artificially altered for convenience of experiments. Commercial pellet feeds and water were randomly fed and bred at standard laboratory conditions (temperature 20-25 ° C., relative humidity 60-70%).
(2) 시료제조(2) Sample preparation
시료에 따라 분말로 사용하거나 에탄올(ethanol)로 추출하였다. 에탄올 추출물을 얻기 위하여 시료를 분쇄한 뒤 시료분말 10 g을 에탄올 100 ml에 넣어 4 시간 동안 교반하였다. 추출물을 거른 뒤 40℃에서 감압농축하였다. 시료는 10% 트윈(Tween) 80에 녹였으며, 10% 트윈 80을 대조군용 시료로 사용하였다.Depending on the sample, it was used as a powder or extracted with ethanol. The sample was ground to obtain an ethanol extract, and then 10 g of the sample powder was put in 100 ml of ethanol and stirred for 4 hours. The extract was filtered and concentrated under reduced pressure at 40 ℃. The sample was dissolved in 10% Tween 80, and 10% Tween 80 was used as a control sample.
(3) 시료 급여(3) sample salary
시료의 1일 투여량은 매주 쥐의 체중을 측정하여 사람의 1일 섭취 허용량과 사람과 쥐의 평균 대사체중(체중3/4) 비율로부터 환산하였는데 사람의 평균 체중은 65 kg, 사람의 시료 1일 섭취 허용량은 본초학 문헌에서 조사되었다 [全國韓醫科大學 本草學 敎授, 本草學, 영림사 (1995)]. 약 2.5 ml의 시료가 3주 동안 1일 2회 경구투여되었다.The daily dose of the sample was determined by measuring the weight of the rats weekly, based on the daily intake allowance of the human and the average metabolic weight ( 3/4 weight) of the human and the rat. Daily allowable intake was investigated in the herbology literature [Won-Guk-Guk-Guk-Guk-Guk-Guk-Gong-Guk, Gong-Guk-Gori, Yeonglim-sa (1995)]. About 2.5 ml of the sample was administered orally twice a day for 3 weeks.
(4) 남성 성기능 개선 활성 조사(4) Male sexual function improvement activity investigation
인위적 발정을 유도하기 위하여 에스트라디올(estradiol) 결정 (시그마사)을 목과 가슴의 피하에 주입하였다. 교미 행동을 관찰하기 위하여 앞 벽과 천장이 투명한 반원통형 케이지 (반경 30 cm, 폭 51 cm, 높이 24.5 cm)를 사용하였다. 15 와트(watt)의 붉은 색 전구를 케이지 15 cm 위에 매달아 케이지 내부를 비추었다. 교미 행동은 마지막 시료 투여 1일후 밤에 조사되었다. 웅성쥐를 관찰 케이지에 넣어 7-8 분간 적응시킨 뒤 수용성 자성쥐 (receptive female)을 넣고 45 분간 교미를 관찰하였다. 에스트로젠이 처리된 암컷의 수용성(receptivity)은 미리 다른 숫컷에 대한 수용을 통하여 확인하였다. 동물에게서 2 m 떨어져서 먼저 (ㄱ) 삽입이 없는 마운팅 빈도 (incidence of mounting without intromission, incidence of pelvic thrust without vaginal penetration) 빈도, (ㄴ) 삽입이 동반된 마운팅 빈도 (incidence of mounting with intromission), (ㄷ) 마운팅 잠복기 (mounting latency: 암컷이 넣어진 후 첫 번 마운팅까지의 경과 시간), (ㄹ) 삽입 잠복기 (intromission latency: 암컷이 넣어진 후 첫 번 삽입까지의 시간), (ㅁ) 삽입간(揷入間) 시간 (inter-intromission period: 연속된 두 삽입간의 평균 시간), (ㅂ) 사정 잠복기 (ejaculatory latency: 첫 번 삽입과 첫 번 사정 사이의 시간), (ㅅ) 사정 후 시간 (postejaculatory interval: 첫 번 사정과 직후 삽입 사이의 시간)이 조사되었다 [Behavior, 29, 154 (1967)]. (ㅇ) 사정 후 시간 조사 후에는 (ㄱ) 삽입이 없는 마운팅 빈도, (ㄴ) 삽입이 동반된 마운팅 빈도, (ㄷ) 사정빈도(incidence of ejaculation)가 조사되었다.In order to induce artificial estrus, estradiol crystals (Sigma) were injected subcutaneously in the neck and chest. A semi-cylindrical cage with a transparent front wall and ceiling (30 cm radius, 51 cm width and 24.5 cm height) was used to observe mating behavior. A 15 watt red bulb was suspended 15 cm above the cage to illuminate the inside of the cage. Mating behavior was examined one night after the last sample administration. Male rats were placed in the observation cage and allowed to acclimate for 7-8 minutes, followed by mating for 45 minutes with a receptive female. Receptivity of estrogen-treated females was confirmed by acceptance of other males. (A) incidence of mounting without intromission, incidence of pelvic thrust without vaginal penetration, 2 m away from the animal, (b) incidence of mounting with intromission, (c ) Mounting latency (elapsed time from first insertion of female to first mounting), (d) Insertion latency (intromission latency: time from insertion of female to first insertion), (ㅁ) between insertions入 間 time (inter-intromission period: average time between two consecutive insertions), (i) ejaculatory latency (time between first insertion and first ejaculation), (g) time after ejaculation (postejaculatory interval: first Time between ejaculation and immediate insertion) was investigated [Behavior, 29, 154 (1967)]. (O) After time assessment, (a) mounting frequency without insertion, (b) mounting frequency with insertion, and (c) incidence of ejaculation were examined.
(5) 혈액생화학 검사(5) blood biochemical test
마지막 시료투여후 하룻밤 절식시키고 에테르(ether)로 마취시켜 개복한 뒤 심장에서 혈액을 채취하여 4℃에서 1,500 x g로 15분간 원심분리해서 혈청을 얻었다. 총 콜레스테롤, HDL-콜레스테롤 및 포도당은 자동 효소법으로 분석되었다 [Clin. Chem., 20, 470 (1974)]. 동맥경화 위험지수 (atherogenic index)는 (총 콜레스테롤 - HDL-콜레스테롤)/HDL-콜레스테롤 식으로 계산되었다 [J. Nutr. Sci. Vitaminol., 41, 485 (1995)]. 총 티록신(thyroxine), 총 테스토스테론(testosterone) 및 프로락틴(prolactin)은 방사면역분석법(radioimmunoassay) 법으로 측정되었다 [Clin. Chem. 28, 1613 (1982)].After the last sample administration, fasted overnight, anesthetized with ether (ether), and then opened, the blood was collected from the heart and centrifuged for 15 minutes at 1,500 x g at 4 ℃ to obtain a serum. Total cholesterol, HDL-cholesterol and glucose were analyzed by automated enzyme method [Clin. Chem., 20, 470 (1974). The atherosclerotic index was calculated by the formula (total cholesterol-HDL-cholesterol) / HDL-cholesterol [J. Nutr. Sci. Vitaminol., 41, 485 (1995)]. Total thyroxine, total testosterone and prolactin were measured by radioimmunoassay method [Clin. Chem. 28, 1613 (1982).
(6) 통계분석(6) Statistical Analysis
측정치는 던칸 다중범위검정 (Duncan's multiple range test)로 분석되었으며 평균치±SEM으로 표시되었다 [SAS Institute, Inc., SAS User's Guide: Statistics, 5th ed., Cary, NC, (1985)].The measurements were analyzed by Duncan's multiple range test and expressed as mean ± SEM [SAS Institute, Inc., SAS User's Guide: Statistics, 5th ed., Cary, NC, (1985)].
(7) 실험결과(7) Experiment result
표 1은 남성 성기능 개선용 기능성 식품의 제조에 사용된 12종 식품소재와 생약재 시료가 경구투여된 위스타(Wistar)계 웅성쥐의 성기능 개선 활성을 조사한 것으로 암컷이 넣어진 후부터 최초 사정후 삽입까지의 관찰 결과이다. 마운팅 잠복기는 실시예 2와 실시예 1에서 대조군에 비하여 의미있게 감소하였다. 삽입 잠복기는 실시예 2, 실시예 1, 구기자, 토사자, 산수유, 홍삼, 로얄 젤리, 오미자, 해삼, 복분자 우슬, 두충 군의 순으로 감소하였다. 삽입간 시간은 실시예 2, 실시예 1,로얄 젤Table 1 examines the sexual function-improving activity of Wistar male rats fed orally administered 12 kinds of food ingredients and herbal medicines used in the manufacture of functional foods for improving male sexual function. Is the observed result. Mounting latency was significantly reduced in Examples 2 and 1 compared to the control. Insertion latency was decreased in the order of Example 2, Example 1, wolfberry, earth and sand, cornus, red ginseng, royal jelly, Schisandra chinensis, sea cucumber, bokbunja pussule, Duchung group. Inter-insertion time is Example 2, Example 1, Royal Gel
리, 토사자, 산수유, 구기자, 홍삼, 해삼, 복분자, 오미자, 우슬, 두충 군의 순으로 감소하였다. 사정 잠복기는 실시예 2, 홍삼, 실시예 1, 로얄 젤리, 두충, 산수유, 오미자, 구기자, 토사자의 순으로 감소폭이 컸다. 사정후 시간은 실시예 2군이 대조군에 비하여 의미있게 감소하였다. 무삽입 마운팅 빈도는 홍삼, 실시예 2, 실시예 1, 사상자, 로얄 젤리, 구기자, 토사자, 복분자의 순으로 작은 값을 보였다. 이상의 결과는 시료 투여군이 대조군에 비하여 짧은 시간에 여러 번의 유삽입 마운팅과 첫 번째 사정을 하였음을 보여주고 있다. 이러한 현상은 실시예 2과 1에서 더욱 크게 나타나서 여러 생약재의 배합과 아스퍼질러스 오리재 (Aspergillus oryzae) SH 및 사카로마이시즈 세리비지애 (Saccharomyces cerevisiae) SH 균주를 이용한 발효에 의해 숫쥐의 교미 행동이 활성화됨을 나타내고 있다.It was decreased in the order of Lee, Tosa, Cornus, Goji, Red ginseng, Sea cucumber, Bokbunja, Schisandra chinensis, Usul, and Duchung group. The latent period of ejaculation was greatest in the order of Example 2, red ginseng, Example 1, royal jelly, tofu, cornus, Schisandra chinensis, wolfberry, and earth and sand. Post-assessment time was significantly reduced in the Example 2 group compared to the control group. Insertion-free mounting frequency was the smallest in the order of red ginseng, Example 2, Example 1, casualties, royal jelly, wolfberry, earth and sand, bokbunja. The above results show that the sample-administered group underwent several insertion and first assessments in a short time compared to the control group. This phenomenon is more pronounced in Examples 2 and 1, and the combination of various herbal medicines and Aspergillus duckwood (Aspergillus oryzae) SH and Saccharomyces cerevisiae (Saccharomyces cerevisiae) The fermentation using the SH strain shows that mating behavior of male rats is activated.
표 2는 45분간 마운팅과 사정 빈도를 조사한 결과이다. 무삽입 마운팅 빈도는 실시예 7, 실시예 4, 사상자, 홍삼, 로얄 젤리, 우슬, 토사자, 산수유, 복분자, 오미Table 2 shows the results of 45 minutes of mounting and assessment frequency. Insertion-free mounting frequency is Example 7, Example 4, casualties, red ginseng, royal jelly, dew, earth and sand, cornus, bokbunja, Omi
자 군의 순으로 대조군에 비하여 의미있게 감소하였다. 유삽입 마운팅 빈도는 실시The order of subgroup was significantly decreased compared to the control group. Insertion Mounting Frequency
예 4, 실시예 7, 로얄 젤리, 해삼, 토사자, 홍삼, 복분자, 구기자, 산수유, 오미자, 사상자, 두충 우슬 군의 순으로 큰 값을 보였다. 마운팅 빈도는 대조군에 비하여 로얄 젤리 군에서 의미있게 증가하였다. 사정 빈도는 실시예 7, 로얄 젤리, 실시예 4, 구기자, 해삼, 홍삼, 토사자, 산수유, 복분자 군의 순으로 대조군에 비하여 큰 값을 보였다. 시료 투여에 의하여 45분간의 무삽입 마운팅 횟수가 감소하고 유삽입 마운팅과 사정 횟수가 증가하였다. 이상의 결과들은 여러 시료의 투여에 의하여 숫쥐의 교미 행동이 활성화됨을 나타내고 있다. 특히 실시예에서 숫쥐의 교미 행동이 크게 활성화되어 여러 생약재의 적절한 배합과 발효가 남성의 성기능 개선에 도움을 줄 수 있음이 입증되었다.Example 4, Example 7, Royal jelly, sea cucumber, earth and sand, red ginseng, bokbunja, wolfberry, cornus, Schisandra chinensis, casualties, Tochung wooseul group showed the largest value. Mounting frequency was significantly increased in the royal jelly group compared to the control. The ejaculation frequency was higher than the control group in the order of Example 7, royal jelly, Example 4, goji berry, sea cucumber, red ginseng, earth and sand, cornus, bokbunja group. Sample insertion decreased the number of non-insertion mounts for 45 minutes and increased the number of insertions and ejaculations. The above results indicate that the mating behavior of male rats is activated by administration of several samples. In particular, the mating behavior of male rats was greatly activated in the examples, and it was proved that proper combination and fermentation of various herbal medicines can help improve male sexual function.
표 3은 시료의 경구투여가 시험쥐의 동맥경화 위험지수 (atherogenic index)와 혈액의 포도당, 총 티록신 (total thyroxine), 프로락틴(prolactin) 및 총 테스토스테론 (total testosterone) 농도에 미치는 영향을 나타낸 것이다. 혈액의 총 콜레스테롤 및 HDL-콜레스테롤 농도로부터 계산된 동맥경화 위험지수는 실시예 5 투여군이 대조군에 비하여 의미있게 작은 값을 보여 주었다. 혈당농도도 실시예 5 투여군에서Table 3 shows the effect of oral administration of the samples on the atherosclerotic risk index and blood glucose, total thyroxine, prolactin and total testosterone concentrations in the mice. The atherosclerosis risk index calculated from the total cholesterol and HDL-cholesterol concentrations in the blood showed a significantly smaller value for the Example 5 administration group than the control group. Blood glucose level in Example 5 administration group
의미있게 감소하였다. 총 티록신 농도는 실시예 5, 오미자, 우슬 및 복분자 투여군에서 의미있게 증가하였다. 프로락틴 농도는 실시예 5와 우슬 투여군에서 의미있게 감소하였다. 총 테스토스테론 농도는 실시예 5, 산수유, 구기자, 토사자 군의 순으로 대Significantly decreased. Total thyroxine concentrations were significantly increased in Example 5, Schisandra chinensis, E. coli and Bokbunja administration groups. Prolactin concentrations were significantly decreased in Example 5 and the urine administration group. The total testosterone concentrations were in the order of Example 5, Cornus, Goji, and Tosa groups.
조군에 비하여 의미있게 증가하였다. 특히 모든 투여군에서 모든 측정치가 생리학적Significant increase compared to the group. In particular, all measurements were physiological
으로 안전한 범위에 있어서 조사된 시료가 안전한 남성 성기능 개선 식품 소재임이In a safe range, the tested sample is a safe male sexual enhancement food material.
입증되었다. 특히 실시예 5에서 모든 측정치가 남성 성기능 개선에 바람직한 경향을Proven. In particular, in Example 5, all measurements showed a favorable trend for improving male sexual function.
보여 여러 생약재의 적절한 배합과 발효가 남성의 성기능을 개선시킬 수 있음이 입증되었다.Proper formulation and fermentation of various herbal medicines have been shown to improve male sexual function.
이상의 실험 결과들은 위에서 조사된 여러 생약재의 배합과 아스퍼질러스 오리재 (Aspergillus oryzae) SH 및 사카로마이시즈 세리비지애 (Saccharomyces cerevisiae) SH 균주를 이용한 발효에 의해 남성 성기능 개선 활성이 우수한 건강식품 원료를 얻을 수 있으며 여러 가공 과정 중 남성 성기능 개선 활성이 유지됨을 나타내고 있다.The results of the above experiments were based on the combination of various herbal medicines investigated above and Aspergillus duck (Aspergillus oryzae) SH and Saccharomyces cerevisiae (Saccharomyces cerevisiae) By fermentation using SH strain, it is possible to obtain a health food raw material having excellent male sexual function improving activity and shows that male sexual function improving activity is maintained during various processing processes.
실험예 2: 남성 성기능 개선 효과 실험 (임상실험)Experimental Example 2: Male sexual function improvement effect (clinical experiment)
(1) 남성 성기능 개선 활성 조사(1) Male sexual function improvement activity investigation
본 연구를 통하여 개발된 남성 성기능 개선용 기능성 식품의 효과가 성기능이 저하된 35세 이상의 남성 30명을 대상으로 조사되었다. 실시예 8에서 제조된 환(丸)을 30일간 7 g씩 하루 3회 섭취시키면서 섭취 20일 후부터 20일간의 성기능 개선 활성을 섭취 전 20일간과 비교하였다. 발기부전과 그 치료결과의 임상평가에 사용되는 15 문항 국제 발기능 지표 [15-question International Index of Erectile Function, 유효 다차원 자기식 설문지 (a validated, multidimensional,self-administered questionnaire), 표 4] 중 질문 3 (삽입 빈도)과 질문 4 (삽입후의 발기유지)를 이용하여 성기능 개선 활성을 평가하였다 [Urology, 49, 822 (1997)]. 두 질문에 대하여 1(거의 안 되거나 결코 안 됨)부터 5(거의 되거나 항상 됨)까지 점수를 매겨 답하게 하였다. 점수 0은 성교가 시도되지 않았음을 의미하였다. 실험군과 비슷한 연령분포를 지닌 40인 정상군의 두 질문에 대한 평균 점수는 4.4였다. 또한 국제 지표 (International Index)에 있는 남성 성기능의 5 분야에서 성기능 개선 활성이 조사되었다. 즉, 발기능 (erectile function: 질문 1∼5, 15; 가능 총점 1∼30), 절정능 (orgasmic function: 질문 9, 10; 가능 총점 0∼10), 성욕 (질문 11, 12; 가능 총점 2∼10), 성교 만족도 (질문 6∼8; 가능 총점 0∼15), 전체적 만족도 (질문 13, 14; 가능 총점 2∼10)의 5 분야에서 성기능 개선 활성이 조사되었다. 각 분야의 점수는 각 질문에 대한 점수를 더하여 얻어졌다. 또한 성기능 개선용 기능성 식품의 섭취자에게 사건 기록 (event log)을 기록하게 하여 성기능 개선 활성을 조사하였는데, 여기에서는 성적자극 유무(有無), 발기 강도 (4등급), 예 또는 아니오로 응답되는 성교의 성공도와 전체적 효능 질문 ("성기능 개선용 식품 섭취가 발기를 개선시켰는가?")이 조사되었다. 국제 지표 (International Index)의 결론은 응답의 크기, 전체적 효능 질문 및 효과를 정성적으로 분석한 사건 기록 (event log)으로 정량화되었다. 부작용은 연구자에 의하여 기록되었다.The effects of functional foods for improving male sexual function were investigated in 30 men over 35 years of age. The sexual function-activating activity of 20 days from 20 days after ingestion was compared with 20 days before ingestion while taking the pills prepared in Example 8 three times a day for 7 days for 30 days. Question 15 of the 15-question International Index of Erectile Function, a validated, multidimensional, self-administered questionnaire, used in the clinical evaluation of erectile dysfunction and its outcomes. Sexual improvement activity was assessed using 3 (insertion frequency) and question 4 (erectile maintenance after insertion) [Urology, 49, 822 (1997)]. The two questions were scored from 1 (nearly or never) to 5 (nearly or always). A score of 0 meant no sexual intercourse was attempted. The mean score for the two questions in the 40-year-old normal group with similar age distribution was 4.4. Sexual improvement activities were also investigated in five areas of male sexual function in the International Index. Erectile function (questions 1 to 5, 15; possible total scores 1 to 30), orc function (orgasmic function: questions 9 and 10; possible total scores 0 to 10), sexual desire (questions 11, 12; possible total scores 2) -10), sexual function improvement activities were investigated in five areas of satisfaction with intercourse (questions 6-8; possible total scores 0-15) and overall satisfaction (questions 13, 14; possible total scores 2-10). Scores in each field were obtained by adding scores for each question. In addition, sexual activity improvement activities were investigated by recording the event log to the intake of functional foods for improving sexual function, in which sexual intercourse responded with or without sexual stimulation, erection intensity (grade 4), yes or no. 'S success and overall efficacy question ("Is eating foods that improve sexual function improved erection?"). The conclusions of the International Index were quantified with an event log that qualitatively analyzed the size of the response, the overall efficacy question, and the effect. Adverse events were recorded by the investigator.
(2) 혈액생화학 검사(2) blood biochemical test
남성 성기능 개선용 기능성 식품의 섭취가 끝난 후 하룻밤 절식시키고 채혈하여 4℃에서 1,500 x g로 15분간 원심분리해서 혈청을 얻었다. 총 콜레스테롤, HDL-콜레스테롤, 중성 지질 및 포도당은 자동 효소법으로 분석되었다 [Clin. Chem., 28, 1671 (1982)]. LDL-콜레스테롤은 [총 콜레스테롤 - (HDL-콜레스테롤 + 중성 지질/5)] 식으로 계산되었다 [Am. J. Clin. Nutr., 33, 2709 (1980)]. 유리 티록신 (free thyroxine), 유리 테스토스테론 (free testosterone) 및 프로락틴은 방사면역분석법으로 측정되었다.After ingestion of functional foods for improving male sexual function, overnight fasting and blood collection were performed by centrifugation at 1,500 x g for 15 minutes at 4 ° C to obtain serum. Total cholesterol, HDL-cholesterol, neutral lipids and glucose were analyzed by automated enzyme method [Clin. Chem., 28, 1671 (1982). LDL-cholesterol was calculated by the formula [Total Cholesterol-(HDL-Cholesterol + Neutral Lipid / 5)] [Am. J. Clin. Nutr., 33, 2709 (1980)]. Free thyroxine, free testosterone and prolactin were measured by radioimmunoassay.
(3) 통계분석(3) Statistical analysis
측정치는 스튜던트 t-검정 (Student's t-test)으로 분석되었으며 평균치±SE로 표시되었다.The measurements were analyzed by Student's t-test and expressed as mean ± SE.
(4) 실험결과(4) Experiment result
국제 지표 (International Index)의 질문 3과 4에 대한 평균 점수는 성기능 개선용 기능성 식품 섭취후가 섭취전에 비하여 의미있게 증가하였다 (P〈0.01) (표 5). 즉 기능성 식품의 섭취에 의하여 질문 3에 대한 점수는 63 % 증가했으며, 질문 4에 대한 점수는 111 % 증가하였다. 이는 남성 성기능 개선용 기능성 식품의 섭취에 의하여 삽입 횟수와 삽입 후의 발기유지가 개선됨을 의미하는 것이다.The mean scores for questions 3 and 4 of the International Index increased significantly after intake of functional foods for improving sexual function (P <0.01) (Table 5). In other words, the intake of functional foods increased the score for Question 3 by 63% and the score for Question 4 increased by 111%. This means that the number of insertions and erection maintenance after insertion are improved by the intake of functional foods for improving male sexual function.
국제 지표 (International Index)에서 발기능의 평균 점수는 성기능 개선용 기능성 식품 섭취전 12.6에서 섭취후 20.7로 64 % 증가하였다 (P〈0.01) (표 6). 절정능(orgasmic function), 성욕, 성교 만족도 및 전체적 만족도의 평균점수도 기능성 식품의 섭취에 의하여 의미있게 증가하였다.The average score of foot function in the International Index increased 64% from 12.6 before intake of functional foods to improve sexual function to 20.7 after intake ( P <0.01) (Table 6). The mean scores of orgasmic function, sexual desire, sexual satisfaction and overall satisfaction were also significantly increased by the intake of functional foods.
실시예 8에서 제조된 환의 섭취는 4등급 발기 횟수를 증가시켜서 성교에 필요한 발기 (3과 4 등급) 횟수를 92 % 증가시켰다 (표 7). 또한 환의 섭취는 성공적성교 횟수를 20일 동안 평균 2.3회에서 4.7회로 증가시켜서 성공적 성교 비율을 27 %에서 62 %로 높였다.Ingestion of the pill prepared in Example 8 increased the number of grade 4 erections to increase the number of erections (grades 3 and 4) required for sexual intercourse by 92% (Table 7). Also, the intake of pills increased the number of successful sexual intercourses from 2.3 to 4.7 on average for 20 days, increasing the rate of successful sexual intercourse from 27% to 62%.
실시예 8에서 제조된 환의 섭취에 의하여 혈액의 총 콜레스테롤과 LDL-콜레스테롤이 의미있게 감소하였으며, 통계적 유의차는 없었지만 HDL-콜레스테롤 농도가 증가하고 혈당농도가 감소하였다 (표 8). 이 결과는 음위의 일반적 원인인 동맥경화와 당뇨병을 본 남성 성기능 개선용 기능성 식품이 예방, 억제할 수 있는 가능성을 보여주는 것이다. 또한 혈액의 유리 티록신 (free thyroxine) 농도가 의미있게 증가하고, 유의차는 없었지만 프로락틴 농도가 감소하고 유리 테스토스테론 (free testosterone) 농도가 증가하여 음위와 관련된 비교적 흔한 내분비계 이상인 갑상선 기능, 생식기능 저하 등을 예방, 억제할 수 있는 가능성을 제시하였다. 그리고 성기능 개선용 기능성 식품 섭취 후의 측정치가 정상범위에 있어서 본 식품의 안전성이 입증되었다.Total cholesterol and LDL-cholesterol in blood were significantly decreased by ingestion of the pill prepared in Example 8, but there was no statistical difference, but HDL-cholesterol concentration was increased and blood glucose concentration was decreased (Table 8). These results show the possibility of preventing and suppressing functional foods for improving male sexual function after arteriosclerosis and diabetes, which are common causes of the genital organs. There is also a significant increase in free thyroxine levels in the blood, and no significant difference, but a decrease in prolactin levels and an increase in free testosterone levels, resulting in thyroid function and decreased fertility, which are relatively common endocrine disorders associated with the tone. The possibility of prevention and suppression was presented. In addition, the safety of this food was proved that the measured value after intake of functional food for improving sexual function was in the normal range.
이상의 결과들은 본 발명에서 제조된 남성 성기능 개선용 기능성 식품이 성기능이 저하된 남성의 성기능을 개선시킬 수 있음을 보여주고 있다. 본 성기능 개선용 기능성 식품을 섭취한 사람들은 삽입빈도, 삽입후의 발기유지 및 발기력이 증가함은 물론 음식물의 소화가 잘 되거나, 밤에 잠이 잘 오고, 일에서 오는 피로감이 감소하는 등의 전반적인 신체의 건강상태가 많이 좋아져서, 본 발명을 통하여 개발된 성기능 개선용 기능성 식품이 일반 성기능 개선용 의약품이 갖지 못한 장점을 지니고 있음을 확인하였다. 최근에 연구개발되어 시판되고 있는 실데나필(ViagraTM)의 경우 두통, 근육통, 위장장애, 조홍(潮紅), 소화불량, 비염(鼻炎), 시각장애 등을 유발하며 심장약과 함께 복용될 경우 사망의 원인이 되기도 한다고 알려져 있다. 발기부전에는 부작용이 없고 이용하기 편리한 치료법이 절실히 요구되고 있다 [J. Urol., 156, 2007 (1996)]. 본 연구에서 개발된 남성 성기능 개선용 기능성 식품은 이러한 조건을 충족시키고 있어서 안전하게 이용될 수 있고, 해면체(海綿體) 주사, 요도에의 의약품 주입, 보철물 삽입 등의 치료법에 비하여 부작용이 적다.The above results show that the functional food for improving male sexual function prepared in the present invention can improve the sexual function of the male having reduced sexual function. People who have consumed functional foods to improve sexual function have an increased body frequency, increased erection retention and erection, as well as better digestion of food, better sleep at night, and reduced fatigue from work. As the health condition of the lot improved, it was confirmed that the functional food for improving sexual function developed through the present invention has the advantage that the general sexual function improving medicine does not have. Sildenafil (Viagra TM ), recently researched and developed, causes headaches, muscle pain, gastrointestinal disorders, scarletness, indigestion, rhinitis, and visual disturbances. It is known to be. Erectile dysfunction is urgently needed for the treatment that has no side effects and is convenient to use [J. Urol., 156, 2007 (1996)]. The functional food for improving male sexual function developed in this study can be used safely because it meets these conditions and has fewer side effects than the treatment methods such as cavernous injection, injection of medicine into the urethra and prosthesis insertion.
복분자, 구기자, 산수유 외 12종의 천연물을 함유하는 본 발명의 남성 성기능 개선용 기능성 식품 조성물은 상기 실험예들의 결과에서 나타난 바와 같이 부작용이 없이 남성의 성기능을 개선함은 물론, 신체의 전반적 건강상태를 좋게 한다.Functional food composition for improving male sexual function of the present invention containing 12 kinds of natural products, such as bokbunja, wolfberry, cornus oil, as well as improving the sexual function of males without side effects, as shown in the results of the experimental examples, the general health state of the body Makes it good
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0028987A KR100463130B1 (en) | 2001-05-25 | 2001-05-25 | The food to improve the sexual function of man |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0028987A KR100463130B1 (en) | 2001-05-25 | 2001-05-25 | The food to improve the sexual function of man |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20020090444A true KR20020090444A (en) | 2002-12-05 |
| KR100463130B1 KR100463130B1 (en) | 2004-12-23 |
Family
ID=27706468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-0028987A KR100463130B1 (en) | 2001-05-25 | 2001-05-25 | The food to improve the sexual function of man |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100463130B1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030063074A (en) * | 2002-08-14 | 2003-07-28 | 이영국 | Health food having release function of asthma and the manufacture method |
| KR20030075250A (en) * | 2002-03-18 | 2003-09-26 | 최성휴 | Natural Energy Pill Gold |
| KR100486961B1 (en) * | 2002-09-23 | 2005-05-03 | 김우영 | The health-supporting food being effective the sexual energy strength and its preparat ion method |
| KR100538717B1 (en) * | 2001-10-31 | 2005-12-26 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
| KR100692173B1 (en) * | 2005-03-23 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| KR100761938B1 (en) * | 2006-12-29 | 2007-10-04 | 주식회사유한양행 | Pharmaceutical composition for preventing or treating impotence induced hyperlipidemia and/or hypertension |
| WO2008115583A1 (en) * | 2007-03-21 | 2008-09-25 | John Mini | Herbal treatments |
| WO2014126269A1 (en) * | 2013-02-12 | 2014-08-21 | 주식회사 한국전통의학연구소 | Pharmaceutical composition for improving male sexual function and for treating infertility |
| WO2018043874A1 (en) * | 2016-08-30 | 2018-03-08 | (주)코엔바이오 | Composition, for preventing hair loss or promoting hair growth, comprising strains showing lipolysis effect |
| KR20190126657A (en) * | 2018-05-02 | 2019-11-12 | 주식회사 한국인삼공사 | Pharmaceutical Composition Comprising Extracts of Eucommia ulmoides Oliver and Achyranthes japonica for Preventing or Treating Andropause syndrome |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100771987B1 (en) * | 2004-12-28 | 2007-10-31 | 전라북도 고창군 | Composition containing Bokbunja extract with testosterone secretion enhancing effect as an active ingredient |
| KR101751211B1 (en) | 2014-12-17 | 2017-06-28 | 홍상근 | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19980061431A (en) * | 1996-12-31 | 1998-10-07 | 백운화 | Tea composition based on herbal medicine effective for nourishing tonic and its manufacturing method |
-
2001
- 2001-05-25 KR KR10-2001-0028987A patent/KR100463130B1/en not_active IP Right Cessation
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100538717B1 (en) * | 2001-10-31 | 2005-12-26 | 주식회사 케이티앤지 | Compositin of Korean Red Ginseng Including Oriental Herbs for Improving Sexual Function and Manufacturing Method the Same and Its Use |
| KR20030075250A (en) * | 2002-03-18 | 2003-09-26 | 최성휴 | Natural Energy Pill Gold |
| KR20030063074A (en) * | 2002-08-14 | 2003-07-28 | 이영국 | Health food having release function of asthma and the manufacture method |
| KR100486961B1 (en) * | 2002-09-23 | 2005-05-03 | 김우영 | The health-supporting food being effective the sexual energy strength and its preparat ion method |
| KR100692173B1 (en) * | 2005-03-23 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| KR100692175B1 (en) * | 2005-03-25 | 2007-03-12 | 손병국 | Health functional food having an energetic and sturdy action |
| KR100761938B1 (en) * | 2006-12-29 | 2007-10-04 | 주식회사유한양행 | Pharmaceutical composition for preventing or treating impotence induced hyperlipidemia and/or hypertension |
| WO2008115583A1 (en) * | 2007-03-21 | 2008-09-25 | John Mini | Herbal treatments |
| WO2014126269A1 (en) * | 2013-02-12 | 2014-08-21 | 주식회사 한국전통의학연구소 | Pharmaceutical composition for improving male sexual function and for treating infertility |
| WO2018043874A1 (en) * | 2016-08-30 | 2018-03-08 | (주)코엔바이오 | Composition, for preventing hair loss or promoting hair growth, comprising strains showing lipolysis effect |
| KR20190126657A (en) * | 2018-05-02 | 2019-11-12 | 주식회사 한국인삼공사 | Pharmaceutical Composition Comprising Extracts of Eucommia ulmoides Oliver and Achyranthes japonica for Preventing or Treating Andropause syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100463130B1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103652361B (en) | Feed for postpartum sow in lactation period of 1-20 days and preparation method thereof | |
| CN103598427B (en) | For reducing feed addictive and the feed of cholesterol content in eggs | |
| KR100463130B1 (en) | The food to improve the sexual function of man | |
| CA2627314C (en) | Composition for treating obesity comprising extract from white kidney beans, red kidney beans, and green tea leaves | |
| CN102697035A (en) | Cordyceps anti-aging pellet | |
| CN103719544B (en) | For improving the feed of meat duck matter | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN105597071A (en) | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia and preparing method thereof | |
| CN101897925B (en) | Medicinal composition for treating metabolic syndrome | |
| CN101904917B (en) | Medicinal composition for removing lead and preparation method thereof | |
| KR100688252B1 (en) | Composition for improving male sexual function | |
| CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN103784754A (en) | Capsules with effects of tonifying kidney and strengthening yang and preparation method thereof | |
| CN103212031A (en) | Traditional Chinese medicine composition for treating primary nephrotic syndrome and preparation method thereof | |
| Sudhakar et al. | Preclinical toxicological evaluation of Aloe vera health drinks in Wistar rats | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| KR102180363B1 (en) | An anti-impotence formula comprising black sesame and yeast hydrolysate | |
| WO2020244501A1 (en) | Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof | |
| US20030096020A1 (en) | Novel herbal composition for the management of bronchial asthma and a process of manufacturing the same | |
| CN112472753A (en) | Composition for protecting liver, traditional Chinese medicine preparation and application | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| CN101249195A (en) | Medicament recuperating astriction and removing toxin stagnation and method of preparing the same | |
| CN105194676B (en) | It is a kind of to treat pharmaceutical composition of hyperlipidemia and preparation method thereof | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20111213 Year of fee payment: 8 |
|
| LAPS | Lapse due to unpaid annual fee |